CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Heidelberg, Germany, March 14, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at the Oppenheimer 27th Annual Healthcare Conference on Tuesday, March 21, 2017 at 4:30 a.m. (ET) in New York.
A live webcast of the conference presentation can be accessed through the "Events" section on the "Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the presentation will be available from Affimed's website for 30 days following the respective conference.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
IR Contact:
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]
Media Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected]
